At 10 μM, cyanidin chloride reduced biotinylated IL-17A binding to IL-17RA-expressing HEK 293 cells and to HeLa cells, assessed by flow cytometry with PBS and anti-IL-17A antibody controls. The reported distributions demonstrate a cellular binding effect; they do not establish a viability margin. [1]
Inhibition of purified IL-17A–IL-17RA binding
Biochemical assay · Purified human IL-17A/IL-17RA–Fc ligand-receptor assay; IL-17E/IL-17RB–Fc and IL-17C/IL-17RE–Fc comparator pairs [1]
A18 inhibited IL-17A/IL-17RA binding with a reported IC50 of 1.68 μM. Comparator receptor-ligand pairs were less efficiently inhibited, rather than completely unaffected at every tested concentration. Figure 1 reports means ± SEM from three independent experiments; DMSO control binding was set to 100%.
Literature-Reported Treatment Conditions
- Treatment concentration
- Serial A18 dilutions; the reported IC50 is an assay endpoint, not a treatment regimen.
- Exposure duration
- Methods describe 1 h receptor incubation followed by 1 h HRP-conjugated anti-Fc incubation in the presence or absence of A18.
- Method
- Ligand-coated plates; IL-17 ligands 2 μg/mL and corresponding receptor-Fc proteins 150 ng/mL, as reported in the shared method.
- Vehicle
- DMSO control in Figure 1 caption
- Reported limits
- No IC50 uncertainty interval is reported with the stated value. The IC50 is specific to this assay.
Methods and source locations
Compound reported in the paper: Cyanidin chloride; Compound label in the paper: A18
Published experiments used another supplier’s cyanidin chloride; they do not validate an Adooq lot.
Figure 1B, 1E–G and caption; Results, A18 specifically inhibits the binding of IL-17A to IL-17RA; Methods, Compounds and Ligand-receptor binding inhibition assay
Inhibition of human IL-17A/IL-17RA–Fc binding: Plate-based ligand-receptor binding assay with HRP-conjugated anti-Fc detection and tetramethylbenzidine substrate; Figure 1E and Results provide the IC50. — Figure 1B, 1E–G and caption; Results, A18 specifically inhibits the binding of IL-17A to IL-17RA; Methods, Compounds and Ligand-receptor binding inhibition assay
Reduced IL-17A binding to live human cells
Cell-based study · HEK 293 cells stably expressing IL-17RA and HeLa cells with endogenous receptors [1]
At 10 μM, A18 reduced the flow-cytometric binding signal of biotinylated IL-17A in both cell models. PBS and an anti-human IL-17A antibody served as negative and positive controls, respectively. Figure 2A presents representative distributions from three experiments; no exact percentage inhibition is extracted.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM A18
- Method
- Cells were exposed to biotinylated IL-17A with PBS, A18 or anti-human IL-17A antibody, then stained with avidin-fluorescein.
- Vehicle
- PBS is identified as the negative control for this assay.
- Co-treatment
- Biotinylated IL-17A is the binding probe; anti-IL-17A antibody is a separate positive-control condition.
- Reported limits
- The cited binding method does not specify ligand concentration or exposure duration. This binding readout is not a viability or clinical-efficacy endpoint.
Methods and source locations
Compound reported in the paper: Cyanidin chloride; Compound label in the paper: A18
Published experiments used another supplier’s cyanidin chloride; they do not validate an Adooq lot.
Figure 2A and caption; Results, A18 specifically inhibits IL-17A-induced gene expression in human and mouse cells (first paragraph); Methods, Compounds and Ligand-receptor binding inhibition assay
Cell-associated biotinylated IL-17A signal: Biotinylated IL-17A binding followed by avidin-fluorescein staining and flow cytometry. — Figure 2A and caption; Results, A18 specifically inhibits IL-17A-induced gene expression in human and mouse cells (first paragraph); Methods, Compounds and Ligand-receptor binding inhibition assay